These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21482676)

  • 1. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.
    Cook RS; Garrett JT; Sánchez V; Stanford JC; Young C; Chakrabarty A; Rinehart C; Zhang Y; Wu Y; Greenberger L; Horak ID; Arteaga CL
    Cancer Res; 2011 Jun; 71(11):3941-51. PubMed ID: 21482676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
    Lahlou H; Müller T; Sanguin-Gendreau V; Birchmeier C; Muller WJ
    Cancer Res; 2012 Jun; 72(12):3080-90. PubMed ID: 22665265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation.
    Williams MM; Vaught DB; Joly MM; Hicks DJ; Sanchez V; Owens P; Rahman B; Elion DL; Balko JM; Cook RS
    Breast Cancer Res; 2017 Sep; 19(1):105. PubMed ID: 28886748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells.
    Samant GV; Sylvester PW
    Cell Prolif; 2006 Dec; 39(6):563-74. PubMed ID: 17109639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.
    Maroulakou IG; Oemler W; Naber SP; Tsichlis PN
    Cancer Res; 2007 Jan; 67(1):167-77. PubMed ID: 17210696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
    Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T; Beerli RR; Maurer F; Koziczak M; Barbas CF; Hynes NE
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8933-8. PubMed ID: 12853564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.
    Young CD; Nolte EC; Lewis A; Serkova NJ; Anderson SM
    Breast Cancer Res; 2008; 10(4):R70. PubMed ID: 18700973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
    Smirnova T; Zhou ZN; Flinn RJ; Wyckoff J; Boimel PJ; Pozzuto M; Coniglio SJ; Backer JM; Bresnick AR; Condeelis JS; Hynes NE; Segall JE
    Oncogene; 2012 Feb; 31(6):706-15. PubMed ID: 21725367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
    Stern DF
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies.
    Porzia A; Lanzardo S; Citti A; Cavallo F; Forni G; Santoni A; Galandrini R; Paolini R
    J Immunol; 2010 Apr; 184(8):4170-7. PubMed ID: 20220087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway.
    Sithanandam G; Smith GT; Masuda A; Takahashi T; Anderson LM; Fornwald LW
    Carcinogenesis; 2003 Oct; 24(10):1581-92. PubMed ID: 12896906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
    Renner O; Blanco-Aparicio C; Grassow M; Cañamero M; Leal JF; Carnero A
    Cancer Res; 2008 Dec; 68(23):9643-53. PubMed ID: 19047141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
    Song X; Fan PD; Bantikassegn A; Guha U; Threadgill DW; Varmus H; Politi K
    Cancer Res; 2015 Mar; 75(6):1035-45. PubMed ID: 25596284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.
    Vaught DB; Stanford JC; Young C; Hicks DJ; Wheeler F; Rinehart C; Sánchez V; Koland J; Muller WJ; Arteaga CL; Cook RS
    Cancer Res; 2012 May; 72(10):2672-82. PubMed ID: 22461506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.
    Weingaertner IR; Koutnik S; Ammer H
    PLoS One; 2013; 8(1):e53510. PubMed ID: 23308242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.